Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Joerg Petersen"'
Autor:
Katja Giersch, Paulina Perez-Gonzalez, Lennart Hendricks, Nora Goldmann, Jonathan Kolbe, Lennart Hermanussen, Jan-Hendrick Bockmann, Tassilo Volz, Annika Volmari, Lena Allweiss, Joerg Petersen, Dieter Glebe, Marc Lütgehetmann, Maura Dandri
Publikováno v:
JHEP Reports, Vol 5, Iss 4, Pp 100673- (2023)
Background & Aims: Pegylated interferon alpha (pegIFNα) is commonly used for the treatment of people infected with HDV. However, its mode of action in HDV-infected cells remains elusive and only a minority of people respond to pegIFNα therapy. Here
Externí odkaz:
https://doaj.org/article/01d54f34c762458ab95d9601864425ef
Autor:
Stefan Bourgeois, Karel van Erpecum, Jean Delwaide, Uwe Naumann, Stefan Christensen, Christophe Moreno, Anita Pathil, Emile Schippers, Nancy van Emmerik, Benoit Caritey, Conrad Fischer, Florence Mercier, Joerg Petersen
Publikováno v:
Cogent Medicine, Vol 7, Iss 1 (2020)
Prescription and efficacy of daclatasvir and sofosbuvir ± ribavirin, including patient-reported outcomes, in routine practice in three European countries: the CMPASS-EU cohort study. Objectives: To identify patient characteristics associated with ro
Externí odkaz:
https://doaj.org/article/02ecdbfc8c5f4994bc47e9e7d931dfb2
Autor:
Peter Buggisch, Karsten Wursthorn, Albrecht Stoehr, Petar K Atanasov, Romain Supiot, Janet Lee, Jie Ting, Joerg Petersen
Publikováno v:
PLoS ONE, Vol 14, Iss 4, p e0214795 (2019)
BackgroundNewer direct-acting antiviral therapies are increasingly becoming the therapy of choice in patients with hepatitis C virus (HCV) infection. Here, we report the safety and effectiveness of sofosbuvir/velpatasvir (SOF/VEL) and ledipasvir/sofo
Externí odkaz:
https://doaj.org/article/3084adf613e241caaac5b5c4e29a906f
Autor:
Joerg Petersen, Maura Dandri
Publikováno v:
Infection and Drug Resistance. 13:3873-3886
Chronic hepatitis B is a numerically important cause of cirrhosis and hepatocellular carcinoma, despite an effective prophylactic vaccine and well-tolerated and effective oral antivirals. Both the incapacity of the immune system to clear hepatitis B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ade26f1c10baf5dcf61a69af4250bd8e
https://doi.org/10.2147/idr.s240472
https://doi.org/10.2147/idr.s240472
Autor:
Kristoffer Riecken, Joerg Petersen, Maura Dandri, Marc Lütgehetmann, Tassilo Volz, Stephan Urban, Boris Fehse, Katja Giersch, Ansgar W. Lohse, Lena Allweiss, Camille Sureau, Oliver D. Bhadra
Publikováno v:
Gut. 68:150-157
ObjectiveHepatitis delta virus (HDV) was shown to persist for weeks in the absence of HBV and for months after liver transplantation, demonstrating the ability of HDV to persevere in quiescent hepatocytes. The aim of the study was to evaluate the imp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b42c55b2dc13bd8d6eecce7b2c9f11ea
https://doi.org/10.1136/gutjnl-2017-314713
https://doi.org/10.1136/gutjnl-2017-314713
Autor:
Joerg Petersen, Sang Hoon Ahn, Jung Hwan Yoon, Man-Fung Yuen, James A. Hamilton, Ingolf Schiefke, Stephen Locarnini, Ki Tae Yoon, Ju Hyun Kim, Hartwig Klinker, Jeong Heo, Henry Lik-Yuen Chan, Michael Manns, T. Schluep, Robert G. Gish, Bruce D. Given, Ching-Lung Lai, Carlo Ferrari
Publikováno v:
Hepatology (Baltimore, Md.)
Background and aims ARC-520, the first an RNA interference (RNAi) therapeutic, was designed to reduce all RNA transcripts derived from covalently closed circular DNA, leading to a reduction in viral antigens and hepatitis B virus (HBV) DNA. Approach
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5349186234cde95fcbd042cd6e93fb1b
https://pubmed.ncbi.nlm.nih.gov/31654573
https://pubmed.ncbi.nlm.nih.gov/31654573
Autor:
Joerg Petersen, Lena Allweiss, Tassilo Volz, Maura Dandri, Ansgar W. Lohse, Marc Lütgehetmann, Joerg M. Pollok, Katja Giersch, Martina Helbig, Jeanette Bierwolf
Publikováno v:
Journal of Hepatology. 63:346-353
Background & Aims The limited availability of hepatitis Delta virus (HDV) infection models has hindered studies of interactions between HDV and infected hepatocytes. The aim was to investigate the antiviral state of HDV infected human hepatocytes in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e262b34aa573440742f9f365bb53fcb
https://doi.org/10.1016/j.jhep.2015.03.011
https://doi.org/10.1016/j.jhep.2015.03.011
Autor:
Joerg Petersen, Maura Dandri
Publikováno v:
Best practiceresearch. Clinical gastroenterology. 31(3)
The mechanisms determining hepatitis B virus (HBV) persistence and pathogenesis are not fully elucidated, but appear to be multi-factorial. Current medication to repress viral replication is available; however, the unique replication strategies emplo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3c6c2f503c93663402478fea5d16c06
https://pubmed.ncbi.nlm.nih.gov/28774409
https://pubmed.ncbi.nlm.nih.gov/28774409
Autor:
Kristoffer Riecken, Katja Giersch, Joerg Petersen, Marc Lütgehetmann, J Kah, Jeanette Bierwolf, Boris Fehse, Stephan Urban, Nicola Oehler, Oliver D. Bhadra, Maura Dandri, Joerg Heeren, Tassilo Volz, Ansgar W. Lohse, J. M. Pollok, Lena Allweiss
Publikováno v:
Hepatology. 60:1483-1493
Chronic hepatitis B virus (HBV) infection has been associated with alterations in lipid metabolism. Moreover, the Na+-taurocholate cotransporting polypeptide (NTCP), responsible for bile acid (BA) uptake into hepatocytes, was identified as the functi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::abac7c378b01b29ef6d0285eb7c44146
https://doi.org/10.1002/hep.27159
https://doi.org/10.1002/hep.27159
Autor:
Simon P. Fletcher, Marc Lütgehetmann, Maura Dandri, Han Ma, Lena Allweiss, Joerg Petersen, Klaus Klumpp, Ansgar W. Lohse, T. Bornscheuer, Tassilo Volz, Katja Giersch
Publikováno v:
Journal of Hepatology. 60:500-507
Pegylated interferon-alpha (PegIFNα) remains an attractive treatment option for chronic hepatitis B virus (HBV) infection because it induces higher rates of antigen loss and seroconversion than treatment with polymerase inhibitors. Although early HB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6237887fe70f4a29c7beea9c0bd12fd
https://doi.org/10.1016/j.jhep.2013.10.021
https://doi.org/10.1016/j.jhep.2013.10.021